【Dosage form】

Liquid for injection

【Specification】

1 mg per 2 mL (0.5 mg per mL) eribulin mesylate in a single-dose vial

【Indication】

Eribulin mesylate injection is a microtubule inhibitor indicated for the treatment of patients with:

1. Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.

2. Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.

【Shelf life】

36months